Hello, and welcome to the 2022 annual meeting of stockholders of Aileron Therapeutics, Inc. Please note that today's meeting is being recorded. You can submit questions at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Manuel C. Aivado, President and Chief Executive Officer of Reine Therapeutics, Inc. Dr. Alves Aivado, the floor is yours. Good morning, and welcome to the 2022 annual meeting of stockholders of Aileron Therapeutics. I am Manuel C. Alves Aivado, President and Chief Executive Officer, and I will be presiding over this meeting. At this time, I call the meeting to order. As we've done the past two years, we are holding our annual meeting in a virtual format, and we're grateful to have everyone join this live webcast. We've designed this meeting to provide you the same rights and opportunities to participate as you would at an in-person meeting. Before we get to the formal part of this meeting, I would like to make some introductions. Joining us at the meeting today are Jeffrey A. Bailey, the Chairman of our board, as well as our directors, William T. McKee, Kathryn J. Morrison, Nolan Sigal, and Josef H. von Rickenbach. Further, we have members of our management team attending. Alan Ennis, our Senior Vice President, Research. Anders N.A. Klarskov, our Vice President of Clinical Development, and Krisztina Vertes, our Vice President of Program Management and Clinical Operations. I would also like to introduce Stuart M. Falber of WilmerHale, the company's legal counsel, Karen Faye, representing PricewaterhouseCoopers, our independent registered public accounting firm. Finally, Patty Peachy, a representative from Computershare Trust Company, our transfer agent. Patty has been appointed to act as inspector of election. In order to conduct an orderly meeting, I call your attention to the rules of conduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions. Please note that various remarks that we may make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC. In addition, these forward-looking statements represent the company's expectations only as of today. While the company may elect to update these forward-looking statements, it specifically disclaims any obligation to do so. Any forward-looking statements should not be relied on as representing the company's estimates or views as of any date subsequent to today. I've received an affidavit from the company's transfer agent, Computershare Trust Company, certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of April 22, 2022. Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Holders of 90,823,597 shares of common stock are entitled to vote at this meeting. The Inspector of election has informed me that they are present at this meeting, either in person or by proxy, a total of 65,179,180 shares of common stock, or approximately 71.76% of all shares entitled to vote at this meeting. Therefore, I hereby declare that a quorum exists. Turning now to the items to be voted on at this meeting, as indicated in the notice of meeting and accompanying documents that were made available to stockholders. The first matter to be voted on is the election of two Class two directors to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified. The nominees for election are William T. McKee and Nolan Sigal. The second matter to be voted on is the approval of an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-25, with the exact ratio to be set within that range at the discretion of our board of directors prior to December 31 of this year. The third matter to be voted on is the approval of an amendment to our Certificate of Incorporation to set the number of authorized shares of common stock at a number determined by calculating the product of 300 million multiplied by 3x the reverse stock split ratio, subject to approval by the stockholders of the reverse stock split and the board's implementation of the reverse stock split. The fourth and final matter to be voted on is the ratification of the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31, 2022. If there are any questions on the proposals, they may be submitted on the virtual meeting website. If asking a question, please also include your name and affiliation to the company. Moderator, do we have any questions at this time? There are no questions at this time. All right. Seeing no questions, we'll move on to voting on the proposals. I hereby declare the polls are now open for each matter to be voted upon today. If you have not yet voted or if you previously voted by proxy and wish to change your vote, you may vote by using the Cast Your Vote link provided on the virtual meeting website and following the instructions there. We will now briefly pause to allow stockholders to vote. Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are closed. Patty, would you please tabulate the votes? Thank you, Patty. We now have the preliminary report of the results of the meeting. Based on this report, each of the nominees for director has been elected as a class two director. The amendments to our certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-25, with the exact ratio to be set within that range at the discretion of our board of directors prior to December 31, 2022, has been approved. The amendment to our certificate of incorporation to set the number of authorized shares of common stock at a number determined by calculating the product of 300 million multiplied by 3x the reverse stock split ratio has been approved. Last but not least, the appointment of PwC has been ratified. The final vote results will be included in the Form 8-K that will be filed within four business days after this meeting. As there is no further business to come before the meeting, I declare the formal part of this meeting adjourned. We will now use our remaining available time to answer appropriate questions from stockholders. Please follow the instructions provided on the virtual meeting website to submit questions. I see there are no questions, and therefore I say thank you again for attending the meeting and for your continued support for our company. Goodbye. This concludes the meeting. You may now disconnect.